Sign In
Buy BGNE
$184.71
+0 (+0%)
At Close: Mar 28, 2025
BeiGene's Stock Is Trading Higher As Brukinsa Drug On Par With JNJ's Imbruvica In Late-Stage Blood Cancer Studies
01:19pm, Wednesday, 28'th Apr 2021
BeiGene Ltd (NASDAQ: BGNE) announced positive results from a planned interim analysis of the Phase 3 ALPINE trial comparing Brukinsa (zanubrutinib) against Johnson & Johnson's (NYSE: JNJ) Imbru
BeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021
04:00pm, Sunday, 11'th Apr 2021
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative me
BeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress
07:00am, Thursday, 08'th Apr 2021
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines wo
BeiGene Announces First Commercial Manufacturing Approval for Its State-of-the-Art Biologics Facility in Guangzhou, China
07:00pm, Wednesday, 07'th Apr 2021
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative me
The Highest-Momentum Holdings of the Decade's Top-Performing Gurus
06:31pm, Friday, 26'th Mar 2021
Investors often look to top fund managers to glean information on the best strategies and generate new investment ideas.
Prime Time's Revival a Lesson for Biotech Investors
02:39pm, Wednesday, 24'th Mar 2021
In Amgen Inc.'s (NASDAQ:AMGN) recent agreement to buy small cancer drug developer Five Prime Therapeutics Inc. (NASDAQ:FPRX) for nearly $2 billion, there seems to be a message for investors in other s
Hutchison China, BeiGene Start Testing Surufatinib/Tislelizumab Combo In Solid Tumor Study
07:51am, Wednesday, 24'th Mar 2021
Hutchison China MediTech (NASDAQ: HCM) has initiated a Phase 1b/2 study of surufatinib combined with BeiGene Ltd's (NASDAQ: BGNE) tislelizumab in patients with advanced solid tumors in the U.S. a
BeiGene Announces Presentation of Clinical and Preclinical Data at the AACR Annual Meeting 2021
04:30pm, Wednesday, 10'th Mar 2021
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces Presentation of Clinical and Preclinical Data at the AACR Annual Meeting 2021
Bumble, NextEra Energy, Wheaton Precious Metals and More Monday Afternoon Analyst Calls
12:20pm, Monday, 08'th Mar 2021
With the trading day about halfway over, the broad markets were pushing higher on the day.
Health Canada Approves BRUKINSA® (Zanubrutinib) for the Treatment of Waldenström's Macroglobulinemia
07:00am, Tuesday, 02'nd Mar 2021
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--Health Canada Approves BRUKINSA® (Zanubrutinib) for the Treatment of Waldenström's Macroglobulinemia
Week In Review: Yuanxin Raises $465 Million For Online Healthcare Company Miaoshou Doctor
01:56pm, Sunday, 21'st Feb 2021
Week In Review: Yuanxin Raises $465 Million For Online Healthcare Company Miaoshou Doctor
BOSTON & CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR
BeiGene's US Application For BRUKINSA In A Type Of Lymphoma, Accepted For Review
09:33am, Wednesday, 17'th Feb 2021
The FDA has accepted for review BeiGene Ltd's (NASDAQ: BGNE) supplemental marketing application seeking approval for BRUKINSA (zanubrutinib) for the treatment of adult patients with Waldenström's
BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (Zanubrutinib) in Waldenström's Macroglobulinemia
07:00am, Wednesday, 17'th Feb 2021
CAMBRIDGE, Mass. & BEIJING, China--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (Zanubrutinib) in Waldenström's Macroglobul
Week In Review: Matridx Raises $32 Million For AI/CRISPR-Cas Pathogen Metagenomics Diagnostic Devices
02:41pm, Sunday, 31'st Jan 2021
Week In Review: Matridx Raises $32 Million For AI/CRISPR-Cas Pathogen Metagenomics Diagnostic Devices
